Inhibitory Effects of Myricetrin and Dihydromyricetin toward α-Glucosidase and Pancreatic Lipase with Molecular Docking Analyses and Their Interaction
Table 1
Interaction between myricetrin and dihydromyricetin on α-glucosidase inhibition.
Ratio
Myricetrin
Dihydromyricetin
α-Glucosidase inhibition (%)
CIa
Fab (%)
CI for Fa
Myricetrin
Dihydromyricetin
Tested concentration (μg/mL)
Calculated concentration (μg/mL)
1 : 1
12.5
12.5
12.80 ± 1.53
1.313
25.0
1.236
19.58
19.58
25.0
25.0
33.40 ± 1.51
1.225
50.0
1.101
34.45
34.45
37.5
37.5
52.48 ± 1.94
1.127
75.0
0.983
60.61
60.61
50.0
50.0
68.42 ± 1.44
0.992
90.0
0.880
106.64
106.64
62.5
62.5
76.68 ± 0.62
0.958
—
—
—
—
1 : 2
8.3
16.7
16.80 ± 2.19
0.821
25.0
0.825
11.47
22.94
16.7
33.3
37.34 ± 2.27
0.831
50.0
0.875
24.38
48.76
25.0
50.0
52.10 ± 2.54
0.851
75.0
0.932
51.84
103.68
33.3
66.7
60.54 ± 2.01
0.913
90.0
0.996
110.22
220.44
41.6
83.4
68.07 ± 2.67
0.929
—
—
—
—
2 : 1
16.7
8.3
44.26 ± 3.36
0.577
25.0
0.438
7.46
3.73
33.3
16.7
54.62 ± 1.10
0.892
50.0
0.727
24.22
12.11
50.0
25.0
62.19 ± 1.03
1.107
75.0
1.207
78.66
39.33
66.7
33.3
72.47 ± 1.17
1.109
90.0
2.007
255.28
127.64
83.3
41.7
78.61 ± 3.92
1.130
—
—
—
—
aCI, combination index. CI ≤ 0.90, 0.90 < CI < 1.10, and CI ≥ 1.10 indicate synergistic, additive, and antagonistic effects, respectively; bFa, fraction affected by the combination dose of myricetrin and dihydromyricetin.
